A nanobody, VHH46, targeting highly pathogenic avian influenza virus of subtype H5 2, 3, 4, and 4b and its application in the preparation of a kit for detecting avian influenza virus.
By developing the nanobody VHH46 targeting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b, constructing recombinant vectors and microbial cells, and preparing a detection kit, the problems of insufficient immune matching and limited delivery of existing antibodies in response to highly pathogenic avian influenza virus of subtype H5 2.3.4.4b were solved, achieving efficient and economical virus detection and protection.
Patent Information
- Application Number
- CN202611462805.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing antibodies have limitations in responding to highly pathogenic avian influenza viruses of the H5 subtype 2.3.4.4b branch, including insufficient immune matching, high preparation costs, limited tissue penetration, and restricted delivery methods, making it difficult to meet the special needs of wildlife rescue and public health safety.
We developed a nanobody, VHH46, targeting highly pathogenic avian influenza virus of subtype H5, clade 2.3.4.4b. We constructed a recombinant vector and recombinant microbial cells to prepare a kit for detecting highly pathogenic avian influenza virus of subtype H5, clade 2.3.4.4b. Utilizing the highly efficient neutralizing activity and in vivo protective effect of the nanobody VHH46, we combined it with an indirect ELISA kit for detection.
It achieves highly efficient and specific binding and detection of highly pathogenic avian influenza virus of subtype H5 2.3.4.4b, reduces preparation costs, improves in vivo protective efficacy, and is suitable for rapid intervention in wildlife and public health security.
Smart Images

Figure CN123106889A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of nanobody technology, specifically relating to a nanobody VHH46 targeting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b and its application in the preparation of a kit for detecting avian influenza virus. Background Technology
[0002] In 1996, the H5 subtype HPAIV was first isolated from diseased and dead domestic geese in Guangdong Province, China, marking the emergence of the H5 subtype HPAIV of the Gs / GD lineage. This lineage of strains spread rapidly among Asian poultry and became endemic, subsequently re-entering its natural host, wild waterfowl. Since the emergence of the Gs / GD lineage H5 HPAIV, its HA gene has undergone significant genetic differentiation during continuous transmission, gradually forming 10 phylogenetic branches (clades 0–9) and multiple subclades. This nomenclature system was proposed and standardized by the World Health Organization (WHO), WOAH, and the Food and Agriculture Organization of the United Nations (FAO). Among them, clade 2.3.4.4 has expanded rapidly since 2014, evolving into eight subclades (2.3.4.4a–2.3.4.4h), including multiple subtypes such as H5N1–6 and H5N8, exhibiting stronger cross-species infectivity and a wider geographical spread. In recent years, clade 2.3.4.4b has experienced explosive outbreaks in wild birds and poultry, almost completely replacing other H5 clades in a short period of time; and has attracted much attention due to its unprecedented global spread and ability to infect a wide range of species (including poultry, wild birds, humans, and other mammals), becoming a major threat to the global poultry industry and public health security.
[0003] The H5 subtype 2.3.4.4b branch of HPAIV continues to circulate globally, causing severe economic losses to the poultry farming industry. It has established a relatively stable transmission and maintenance chain in wild birds and continues to spread to various wild mammals, demonstrating significant cross-species transmission capabilities, posing a serious threat to wildlife conservation, the aquaculture industry, and public health security. Currently, the main control measures for H5 subtype HPAIV still have significant limitations in dealing with the 2.3.4.4b branch: this branch of the virus mutates frequently, easily leading to insufficient immune matching between vaccine strains and circulating strains; vaccine immunization is mainly applicable to poultry population prevention, and cannot meet the special needs of wildlife rescue, protection of rare and endangered species, and rapid intervention after infection exposure; existing antiviral drugs are limited by factors such as drug resistance risk, narrow therapeutic window, and limited control of severe infections. Furthermore, although traditional antibodies have good specificity and neutralizing activity, they generally suffer from high preparation costs, demanding storage and transportation conditions, and the potential to induce drug-resistant antibody responses in heterologous applications.
[0004] In recent years, research on neutralizing antibodies against the H5 subtype HPAIV has developed rapidly, with several broad-spectrum human or murine monoclonal antibodies reported, capable of cross-neutralizing multiple H5 or subtype viruses in vitro and in vivo. Existing antibodies target the HA head receptor binding region, HA stem fusion-related region, or conserved functional domains of the NA, enabling cross-neutralization of multiple H5 subtype viruses in vitro and in vivo, and even exhibiting some inhibitory activity against certain heterogeneous influenza viruses. However, current research indicates that traditional IgG monoclonal antibodies still suffer from high preparation costs, limited tissue penetration, long engineering modification cycles, and limited delivery methods in grassroots prevention and control and emergency field applications. Furthermore, the in vitro neutralizing titers of existing antibodies are mostly concentrated in the range of 0.1–10 μg / mL, and in animal experiments, intravenous or intraperitoneal administration of 5–10 mg / kg is typically required to achieve complete protection against lethal challenge. While some VHH-Fc fusion proteins targeting HA or NA have shown promising preventative or therapeutic effects in mouse models in recent years, most studies have focused on strains such as H5N1 or H1N1, offering limited coverage of the currently prevalent 2.3.4.4b branch of H5 strains. Therefore, screening for novel antibody molecules that cover the currently prevalent branches and possess both highly efficient neutralizing activity and in vivo protective effects is crucial for expanding the H5 subtype HPAIV antibody technology pipeline. Summary of the Invention
[0005] The purpose of this invention is to provide a method for detecting HPAIV of subtype 2.3.4.4b of H5 from wild birds.
[0006] This invention provides a nanobody VHH46 targeting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b. The amino acid sequence of CDR-1 of the nanobody is shown in SEQ ID NO.13, the amino acid sequence of CDR-2 of the nanobody is shown in SEQ ID NO.15, and the amino acid sequence of CDR-3 of the nanobody is shown in SEQ ID NO.17.
[0007] Further specifying, the amino acid sequence of FR1 of the nanobody is shown in SEQ ID NO.12, the amino acid sequence of FR2 of the nanobody is shown in SEQ ID NO.14, the amino acid sequence of FR3 of the nanobody is shown in SEQ ID NO.16, and the amino acid sequence of FR4 of the nanobody is shown in SEQ ID NO.18.
[0008] This invention provides a nanobody VHH46 targeting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b, wherein the full length of the variable region of the nanobody VHH26 is shown in SEQ ID NO.20.
[0009] The present invention provides a gene encoding the above-mentioned nanobody.
[0010] This invention provides a kit for detecting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b, the kit comprising the aforementioned nanobody VHH46.
[0011] The present invention provides a recombinant vector containing the above-mentioned genes.
[0012] The present invention provides a recombinant microbial cell containing the aforementioned genes.
[0013] This invention provides the application of the above-mentioned nanobody VHH46 against highly pathogenic avian influenza virus of subtype H5 2.3.4.4b, the above-mentioned gene, the above-mentioned recombinant vector, or the above-mentioned recombinant microbial cells in the preparation of a kit for detecting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b.
[0014] To further specify, the nanobody VHH46 mentioned above in the kit is the detection antibody, and the HRP-labeled anti-His-Tag antibody is the capture antibody.
[0015] To be further specified, the kit is an indirect ELISA kit.
[0016] Beneficial effects: The VHH46-His nanobody has an EC50 of 0.4181 μg / mL, exhibits excellent binding ability to the HA antigen, and also demonstrates specific binding ability to the 2.3.4.4b branch strain. Attached Figure Description
[0017] Figure 1 PCR identification of pFastBac HT-B-H5; M: DNA Marker; 1: H5 gene; Figure 2 PCR identification of recombinant rod-like particles; M: DNA Marker; 1: H5 gene recombinant Bacmid positive clone; 2: empty vector control; Figure 3 Comparison of Sf9 cell morphology: (A) Untransfected control; (B) Negative rod-cell transfection control; (C) P1 generation virus infection; (D) P2 generation virus infection; (E) P3 generation virus infection; (F) P4 generation virus infection. Figure 4 To identify the expression of recombinant H5 protein using Western blotting; M: protein molecular weight standard; 1: empty vector control; 2: uninfected control; 3: recombinant H5 protein; Figure 5 The results of purification and concentration of recombinant H5 protein; M: protein molecular weight standard; 1: purified and concentrated recombinant H5 protein; Figure 6 Functional validation of recombinant H5 protein; (A) Western Blot to identify the reactivity of recombinant H5 protein with positive chicken serum; M: protein molecular weight standard; 1: empty vector control; 2: recombinant H5 protein; (B) ELISA to identify the reactivity of recombinant H5 protein with chicken serum; Figure 7 The results of the alpaca serum antibody titer test are as follows: (A) HI test to detect serum reactivity with the virus; (B) ELISA test to detect serum reactivity with recombinant H5 protein; (C) ELISA test to detect the antibody titer of the last serum test. Figure 8 Separation of PBMCs; indicated by the red arrow, appearing as a white cloud; Figure 9 Identification of VHH gene PCR products; (A) Identification of first-round PCR amplification products; M: DNA Marker; 1–4: VH and VHH gene; (B) Identification of second-round PCR amplification products; M: DNA Marker; 1: VHH gene; Figure 10 Identification of VHH and pComb3X vectors by enzyme digestion; M: DNA Marker; 1–4: pComb3X vector digestion products; 2: VHH digestion products; Figure 11 For phage library positivity identification; M: DNA Marker; 1–48: bacterial culture PCR products; Figure 12pLVSIN-H5 PCR identification; M: DNA Marker; 1: H5 gene; Figure 13 Construction of a stable 293T-H5 expression cell line; (A) Untransfected cells; (B) Cells 24 h after transfection; (C) Cells 48 h after transfection; (D) Cells 72 h after transfection; (EH) Bright field images corresponding to AD; Figure 14 Screening for 293T-H5 stably expressing cell lines; (A) Uninfected cells; (B) First-generation screening cells; (C) Second-generation screening cells; (D) Third-generation screening cells; (E–H) Bright-field images of A–D; Figure 15 To identify H5 protein expression in 293T-H5 cells using Western blotting; M: protein molecular weight standard; 1: membrane of uninfected 293T cells; 2: cell membrane of stable 293T-H5 cell line; Figure 16 To identify H5 protein expression in 293T-H5 cells using IFA; Figure 17 To identify the reactivity of 96 crude nanobody extracts with H5 protein using Phage Elisa; Figure 18 The amino acid sequence of 30 VHH strains was compared; Figure 19 pET-22b-VHH-His PCR identification; M: DNA Marker; 1–9: VHH6, VHH8, VHH26, VHH36, VHH45, VHH46, VHH70, VHH80, VHH83 genes; Figure 20 For the expression and purification identification of VHH-His; M: protein molecular weight standard; (A) Western blot identification of VHH-His expression (B) SDS-PAGE analysis of VHH-His purity; Figure 21 EC50 of VHH-His was determined by ELISA; (A) EC50 of VHH36-His, VHH45-His, VHH26-His, VHH8-His and VHH70-His; (B) EC50 of VHH83-His, VHH46-His, VHH6-His and VHH80-His; Figure 22 The reactivity of 9 VHH-His strains to 10 viral strains was determined by ELISA. Detailed Implementation pFastBac HT-B vector (brand: Invitrogen, product number: 10584-027); Packaging plasmid gag-pol (Addgene, 14887), envelope plasmid VSV-G (Addgene, 8454). Prokaryotic expression vector pET-22b(+) (Huijun Biotechnology, FT603); A / tundra swan / Inner Mongolia / WF41 / 2021(H5N1)
W41
[0018]
[0019] Example 1. Preparation and testing of H5 subtype HPAIV inactivated virus immunogen from wild birds. 1. Virus strain culture, inactivation and purification (1) Virus culture: Dilute the original virus solution with sterile PBS containing 1% penicillin and streptomycin to a concentration of 10. 3 -10 5 EID 50 / mL, the diluent was filtered and sterilized using a 0.22 μm microporous membrane; 5 SPF chicken embryos were inoculated for each dilution (0.1 mL / embryo, allantoic cavity injection), and a PBS negative control group (5 SPF chicken embryos) was set up; the embryos were incubated at 37°C for 72 h, and dead chicken embryos within 24 h after inoculation were removed (considered as non-specific death) and re-inoculated. The time of death of chicken embryos was recorded by candling every 12 h. The dead chicken embryos and the surviving chicken embryos after 72 h were placed at 4°C for more than 4 h, and the clear chicken embryo allantoic fluid (about 4–8 mL / embryo) was collected for hemagglutination test.
[0020] (2) Chicken embryo median lethal dose (EID) 50 Assay: Chicken embryo allantoic fluid was serially diluted 10-fold with sterile PBS containing 1% penicillin and streptomycin (10... -1 -10 -10 The diluent was sterilized by filtration through a 0.22 μm microporous membrane. Five SPF chicken embryos were inoculated at each dilution (0.1 mL / embryo, allantoic injection), and a PBS negative control group (five SPF chicken embryos) was established. The embryos were incubated at 37°C for 72 h. Embryo mortality was recorded every 24 h, and embryos that died within 24 h after inoculation were discarded and re-inoculated. Embryos that died after 24 h and those that survived after 72 h were refrigerated at 4°C for at least 4 h. Allantoic fluid was collected and subjected to a hemagglutination (HA) test; a titer ≥2 was required. 3 The result was positive. The EID of each strain was calculated using the Reed-Muench method. 50 .
[0021] (3) Virus inactivation: Collection titer ≥2 6Allantoic fluid was centrifuged at 5000×g for 10 min at 4℃ in sterile centrifuge tubes to remove cell debris and impurities. The supernatant was collected and filtered through a 0.22 μm microporous membrane for sterilization. β-propiolactone was added to the virus solution at a ratio of 1:3000 (v / v), mixed thoroughly, and inactivated at 4℃ for 24 h. The reaction was terminated by incubating in a 56℃ water bath for 30 min. The HA titer was measured again after inactivation to confirm that the antigenicity of the HA protein was not affected. Five SPF chicken embryos (0.2 mL / embryo) were inoculated with the inactivated virus solution, and a positive control group with non-inactivated virus strain was set up. The HA activity of the allantoic fluid was measured after 96 h. A HA titer of 0 was considered negative. Inactivated viral RNA was extracted from the allantoic fluid using an automated nucleic acid extractor. Quantitative real-time PCR was performed using H5 subtype-specific primers. A Ct value ≥40 or no amplification curve was considered negative.
[0022] (4) Purification of virus by sucrose density gradient centrifugation First ultracentrifugation to concentrate the virus: The inactivated virus solution was transferred into a 40 mL ultracentrifuge tube, the tube weight was balanced (difference ≤ 0.01 g), and centrifuged at 30000 × g at 4°C for 1 h (using a P70AT rotor). After centrifugation, the supernatant was discarded, and the virus precipitate at the bottom of the tube was slowly resuspended in 2 mL of sterile PBS and thoroughly dissolved for later use.
[0023] Sucrose density gradient purification: 30% and 60% (w / v) sucrose solutions were prepared using PBS as solvent. 19 mL of 30% sucrose was slowly added to a centrifuge tube using a syringe, followed by an equal volume of 60% sucrose injected through the syringe inserted into the bottom of the tube, allowing a natural gradient to form at the bottom. Then, 2 mL of the virus solution obtained in the previous step was carefully added dropwise to the surface of the upper layer of the sucrose gradient, avoiding disturbance to the gradient layer. After balancing the centrifuge tubes, centrifugation was performed at 30000 × g at 4°C for 1 h. At the end of centrifugation, a bright band was observed at the interface between the 30% and 60% sucrose solutions, representing the purified virus.
[0024] Remove sucrose and collect the virus: Carefully aspirate the bright band (i.e., the virus layer at the 30%–60% sucrose interface) using a syringe and transfer it to a new ultracentrifuge tube. Add PBS to the tube until full, and centrifuge again at 30000×g, 4℃ for 1 h to precipitate the virus. After centrifugation, discard the supernatant and resuspend the virus precipitate in 1 mL of PBS to obtain the purified H5 subtype HPAIV virus solution, which should be stored at -80℃ for later use.
[0025] 2. Preparation and quality testing of immunogens (1) Vaccine emulsification: Based on hemagglutination titer standardization, the inactivated H5 subtype HPAIV antigen used is 2 12HA units, with a corresponding total protein concentration of approximately 0.25 mg / mL, and this value is only used for estimation and reference between batches. The inactivated virus is mixed with an equal volume of Freund's complete / incomplete adjuvant, and emulsified using a double-barrel syringe until a water-in-oil (W / O) state is achieved, where the emulsion is qualified if it does not diffuse when dripped into water.
[0026] (2) Sterility test: Take 100 μL of the emulsified vaccine to inoculate LB medium, incubate at 37°C for 72 h, and the sample is judged to be sterile if no turbidity is observed.
[0027] (3) Mouse immunization verification: To verify the biological safety and immunogenicity of the inactivated H5 subtype HPAIV immunogen, 6-week-old SPF BALB / c mice are randomly divided into a vaccine immunization group, an adjuvant control group and a blank control group (n = 5 in each group). On day 0, the vaccine immunization group is subcutaneously injected with 0.2 mL containing 2 12 HA units of inactivated virus antigen emulsified vaccine, and the adjuvant control group and the blank control group are given corresponding control treatments respectively; a booster immunization is performed on day 14. Serum is collected 14 days after the booster immunization, and the hemagglutination inhibition (HI) test is used to detect the H5-specific antibody response (HI ≥ 2 5 is judged as positive). The general state of the mice is observed daily during the experiment to evaluate the safety of the immunization process.
[0028] (4) Storage: After aliquoting, store at 4°C (for ≤ 1 month) or store long-term at -80°C, and avoid repeated freezing and thawing.
[0029] Results: The immunogen strain used in this study is a wild bird-derived H5 subtype HPAIV monitored and identified by our team, whose whole genome has been sequenced in previous studies and confirmed to belong to the 2.3.4.4b clade. The strain information is shown in Table 1.
[0030] Calculated by the Reed-Muench method, the EID of BQ6 and W41 50 are 8.83 Log 10 EID 50 / 0.1 mL and 9.38 Log 10 EID 50 / 0.1 mL respectively, indicating that both strains have high replication titers in chicken embryos, meeting the requirements for subsequent inactivation and immunogen preparation.
[0031] Table 1 Immunogen strain information
[0032] After inactivation treatment with β-propiolactone, the HA titers of BQ6 and W41 did not decrease significantly compared with those before inactivation (Table 2), indicating that the antigenicity of HA proteins was preserved. When the inactivated virus solution was inoculated into SPF chicken embryos, no HA activity was detected in the allantoic fluid within 96 h; simultaneously, quantitative real-time PCR showed no viral RNA amplification signal, indicating that BQ6 and W41 had been completely inactivated.
[0033] After ultracentrifugation concentration and purification via 30%–60% sucrose density gradient centrifugation, a clear viral band was observed at the sucrose interface between the two layers. The viral band was recovered and sucrose was removed to obtain a purified viral precipitate. The concentrated viral solution, resuspended in PBS, became clear and transparent, and the HA titer increased to log212 (Table 2), indicating that host-derived impurities were effectively removed and a high-purity inactivated viral preparation was obtained.
[0034] Table 2 Comparison of hemagglutination titers of the strains
[0035] 3. Preparation and quality inspection results of the immunogen Inactivated virus W41 and Freund's Complete Adjuvant (FCA), and inactivated BQ6 and Freund's Incomplete Adjuvant (FIA) were thoroughly emulsified using a dual-barrel syringe to form a stable water-in-oil emulsion that did not diffuse when dropped into water, meeting the requirements for immunization. No bacterial growth was observed after 72 hours of incubation on LB medium, indicating that the preparation process was aseptic.
[0036] No significant adverse reactions were observed in mice during the immunization process, and the activity level of mice in all groups remained normal. Following booster immunization, H5-specific antibodies (HI≥2) were detectable in the serum of all mice in the vaccine-immunized groups. 5 ), while no specific antibodies were detected in either the adjuvant control group or the blank control group.
[0037] The above results indicate that the inactivated H5 subtype HPAIV immunogen has good biosafety in vivo and can induce a specific immune response against the HA protein, which can be used for subsequent alpaca immunization.
[0038] Example 2. Expression, purification, and immunogen preparation of recombinant H5 protein from an insect baculovirus system. 1. Construction and identification of pFastBac HT-B-H5 recombinant plasmid (1) Sequence design and synthesis The shared sequence CDS region was translated into an amino acid sequence. The transmembrane region position was predicted using TMHMM 2.0. The C-terminal transmembrane region (approximately amino acids 532-567) was removed, while the signal peptide and extracellular functional domain (amino acids 1-531) were retained. Homologous arms of the pFastBac HT-B vector were added to both ends of the sequence, and gene synthesis was commissioned to Jilin Kumei Biotechnology Co., Ltd.
[0039] Immunogen: Recombinant H5 protein amino acid sequence, with the C-terminal transmembrane region (approximately amino acids 532-567) removed, while retaining the signal peptide and extracellular functional domain (amino acids 1-531), SEQ ID NO: ; (2) Homologous recombination of the target fragment and the vector The synthesized H5 gene with homologous arms was homologously ligated with the linearized pFastBac HT-B vector, and the system (10 μL) is shown in Table 3.
[0040] Table 3 Homologous recombination linkage system
[0041] Connect at 37°C for 30 minutes.
[0042] (3) Transformation of recombinant plasmids Add 10 μL of the product to 30 μL of DH5α competent cells, incubate on ice for 30 min, heat shock at 42°C for 90 s, incubate on ice for 3 min, add 200 μL of antibiotic-free liquid LB medium, and incubate at 37°C with shaking at 220 rpm for 1 h. Spread the bacterial culture evenly on solid LB medium (Amp+) and incubate overnight at 37°C.
[0043] (4) Plasmid extraction (small quantity) Single colonies were picked and cultured in liquid LB medium (Amp+) at 37°C and 220 rpm for 16 h. A certain amount of bacterial suspension was centrifuged at 4°C and 8000 ×g for 2 min. The precipitate was resuspended with resuspension buffer, lysis buffer was added, and the mixture was inverted and mixed. Neutralization buffer was added, and the mixture was inverted and mixed again. The supernatant was then centrifuged at 4°C and 8000 ×g for 5 min. The supernatant was transferred to a Gene JET rotary column and centrifuged at 4°C and 8000 ×g for 1 min. Wash buffer was added, and the column was centrifuged at 8000 ×g for 1 min. This process was repeated twice. An empty column was then centrifuged at 4°C and 8000 ×g for 2 min. The column was transferred to a new 1.5 mL EP tube, elution buffer was added, and the column was incubated for 2 min. The plasmid was obtained by centrifugation at 4°C and 8000 ×g for 2 min. The concentration was measured using a NanoDrop microspectrophotometer.
[0044] (5) PCR identification of positive clones and sequencing The extracted plasmid was identified by PCR using H5 gene-specific primers. The specific primer sequences are shown in Table 4, and the PCR system (20 μL) is shown in Table 4.
[0045] Table 4 H5 gene-specific primer sequences
[0046] Table 5 PCR Identification System
[0047] Reaction conditions: 95°C for 5 min; 92°C for 1 min, 58°C for 30 s, 72°C for 1 min, 35 cycles; 72°C for 10 min; 4°C infinity.
[0048] The PCR products were subjected to agarose gel electrophoresis, and the products with the correct band size were sent to Jilin Kumei Biotechnology Co., Ltd. for sequencing.
[0049] Results: The extracellular region (with the C-terminal transmembrane region deleted) of the H5 gene from strain A / greylag goose / Netherlands / 20016414-001 / 2020 (H5N8) was cloned into the pFastBac HT-B vector to construct the pFastBac HT-B-H5 recombinant plasmid. After transformation with DH5α, single clones were randomly selected for plasmid extraction and PCR (…). Figure 1 Identification showed that the target fragment size was consistent with the theoretical value, approximately 1600 bp. Sequencing verification confirmed that the inserted fragment sequence was completely identical to the designed sequence, indicating that the recombinant plasmid pFastBac HT-B-H5 was successfully constructed.
[0050] 2. Preparation of recombinant baculovirus (1) Transformation of DH10Bac competent cells and transposition Take 4 μL of the correctly sequenced pFastBac HT-B-H5 plasmid and add it to 50 μL of DH10Bac competent cells. Incubate on ice for 30 min, heat shock at 42℃ for 45 s, incubate on ice for 2 min, add 900 μL of antibiotic-free SOC medium, and incubate at 37℃ with shaking at 200 rpm for 4 h. Take 20 μL of the bacterial culture and dilute it with 200 μL of SOC medium, spread it evenly on solid LB medium (Kana+, Gent+, Tet+, X-gal, IPTG), and incubate at 37℃ for 48 h until blue-white spots are clearly visible.
[0051] White single colonies (containing recombinant Bacmid) were picked and cultured in liquid LB medium (Kana+, Gent+, Tet+) at 37℃ and 220 rpm for 16 h. Colony identification was performed by M13 universal primers. Primer sequences are shown in Table 6, and PCR system (20 μL) is shown in Table 7.
[0052] Table 6 M13 universal primer sequences
[0053] Table 7 PCR Identification System
[0054] Reaction conditions: 94°C for 5 min; 94°C for 45 s, 55°C for 45 s, 72°C for 5 min, 35 cycles; 72°C for 7 min; 4°C infinity.
[0055] The PCR products were subjected to agarose gel electrophoresis to verify the band size.
[0056] (2) Extraction and identification of recombinant baculovirus plasmids Transfer 1.5 mL of correctly identified bacterial culture to a centrifuge tube, centrifuge at 9000 ×g for 1 min, and discard the supernatant. Add 400 μL of resuspension buffer (containing RNase A) to completely resuspend the bacterial cells. Add 400 μL of lysis buffer, gently invert and mix 5 times (until the solution becomes clear), and incubate for 5 min. Add 400 μL of precipitation buffer, immediately invert and mix 10 times, and incubate for 10 min. Centrifuge at 12,000 ×g for 10 min, transfer the supernatant to an equilibration column, and remove the liquid by gravity. Add 2.5 mL of washing buffer, remove the liquid by gravity, and repeat twice. Transfer the column to a new 2 mL EP tube, add 0.9 mL of elution buffer, and remove the liquid by gravity. Add 0.7 times the volume of isopropanol (approximately 600 μL), mix well, and incubate on ice for 10 min. Centrifuge at 12,000 ×g at 4°C for 5 min, discard the supernatant, air dry, add 40 μL TE buffer and dissolve on ice for 10 min to obtain recombinant baculovirus plasmid.
[0057] (3) PCR identification Plasmid PCR identification was performed using universal primers of M13. The primer sequences are the same as those in Table 6. The PCR system (20 μL) is shown in Table 8.
[0058] Table 8 PCR Identification System
[0059] The reaction conditions are the same as in (1).
[0060] The PCR products were subjected to agarose gel electrophoresis, and the products with the correct band size were sent to Jilin Kumei Biotechnology Co., Ltd. for sequencing.
[0061] result: The correctly sequenced pFastBac-HT-B-H5 plasmid was transformed into DH10 Bac competent cells, and blue-white screening was performed. Blue (empty vector) and white (recombinant plasmid) colonies were picked separately, and the Bacmid plasmid was extracted using a baculovirus shuttle vector Bacmid mini-extraction kit. Using this plasmid as a template, PCR identification was performed using universal sequencing primers M13-F / M13-R. The results showed ( Figure 2 The positive clone amplified a specific band of approximately 4000 bp, consistent with the theoretical size, while the negative control amplification product was approximately 300 bp. This is consistent with the theoretical size between the M13 primers in the empty Bacmid (pFastBac-HT-B), indicating that the H5 gene has been successfully inserted into the Bacmid backbone via transposition to obtain Bacmid-H5.
[0062] Example 3. Recombinant baculovirus transfection of Sf9 cells and virus harvesting I. (1) Transfection and harvest of P1 generation virus Sf9 cells were seeded in 6-well plates (2 × 10⁻⁶ cells per well).6 Cells / well), incubated overnight at 27°C. To prepare the transfection complex, add 10 μL PEI transfection reagent + 100 μL serum-free medium to tube A, and 1 μg Bacmid-H5 + 100 μL serum-free medium to tube B. Mix tubes A and B and incubate at room temperature for 30 min. Discard the medium from the 6-well plate and replace with 1 mL of serum-free medium. Add the complex to the cells and incubate at 27°C for 5 h. Replace with 2 mL of complete medium containing 2% FBS and continue incubation at 27°C for 5 days. Collect the supernatant, centrifuge at 500 ×g for 5 min at 4°C to remove cell debris. Filter through 0.22 μm filter, aliquot, and store at 4°C, labeled as P1 virus.
[0063] (2) P2 generation virus amplification and harvest Infect Sf9 cells with 150 μL of P1 virus, following the same procedure as (1). Continue culturing at 27℃ for 4 days, then harvest P2 virus, following the same procedure as (1).
[0064] (3) Amplification and harvesting of P3 generation virus Sf9 cells were inoculated into T25 cell culture flasks and incubated overnight at 27°C. 200 μL of P2 virus was used to infect Sf9 cells, following the same procedure as (1). The cells were then cultured at 27°C for 4 days to harvest P3 virus, following the same procedure as (1). The cells were stored at 4°C for ≤1 month and at -80°C for ≥1 year (avoid repeated freeze-thaw cycles).
[0065] Results: Empty Bacmid cells that were negative by PCR and successfully constructed rBacmid-H5 cells were transfected into Sf9 cells, respectively. Cell culture supernatant was collected on day 5 to obtain P1 generation recombinant baculovirus. Sf9 cells were then infected with the P1 virus for amplification culture, and cytopathic effect (CPE) was observed within 72 h post-infection.
[0066] P2, P3, and P4 generation viruses were obtained through continuous amplification. Cell morphology was compared by microscopic photography on day 5 after each generation. Figure 3 Compared to P1 () Figure 3 C), after P2–P4 generation virus infection of Sf9 cells, the time of CPE appearance was significantly earlier, and the severity of the lesions gradually increased, manifested as increased cell volume, rounding, and gradual detachment. Figure 3 D, E, F). In contrast, the untransfected control group ( Figure 3 A) and negative band-11 transfection control group ( Figure 3 B) The cell morphology remained normal, indicating that the recombinant baculovirus was successfully amplified and had good infective activity.
[0067] 2. The harvested P4 generation recombinant baculovirus was centrifuged and filtered before being aliquoted and stored for subsequent Sf9 cell H5 protein expression experiments.
[0068] 1. Identification of recombinant baculovirus by Western Blot (1) Cell lysis and protein extraction The following groups were set up: a recombinant baculovirus infection group, an empty vector virus control group, and an uninfected cell control group. In the infection group, P3 generation virus was inoculated into Sf9 adherent cells, while the empty vector control group was inoculated with pFastBac HT-B empty vector baculovirus without the H5 gene. After 3 days, the culture medium was discarded, and the cells were washed twice with PBS. 80 μL of pre-chilled lysis buffer (RIPA Buffer) and 1 μL of Benzonase endonuclease were added to each flask, and the cells were lysed on ice for 30 min. The lysate was scraped from the cells and transferred to pre-chilled centrifuge tubes. The cells were centrifuged at 12,000 rpm at 4°C for 15 min, and the supernatant (total protein lysis buffer) was transferred to a new tube.
[0069] (2) Western Blot identification Results: Western blot analysis was performed to identify the expression of H5 protein in Sf9 cells using P4 generation recombinant baculovirus. The results showed ( Figure 4 A specific protein band of approximately 65 kDa was detected in the recombinant baculovirus-infected group, while no corresponding band was detected in the empty vector virus control group and the uninfected cell control group. These results indicate that the prepared recombinant baculovirus can successfully express the H5 protein in Sf9 cells.
[0070] 2. Purification, dialysis, and concentration of recombinant H5 protein: Recombinant H5 protein expressed in Sf9 cells was purified and concentrated using Ni-NTA affinity chromatography, and the product was analyzed by SDS-PAGE. The results showed that ( Figure 5 After purification, a clear and dominant protein band was observed at approximately 65 kDa in the concentrated sample, with a purity of about 90%, which meets the needs of subsequent immunological experiments and functional studies.
[0071] 3. Functional validation of recombinant H5 protein (1) Western Blot verification of HA antigen epitope function
[0072] Empty vector expression products and negative controls were set up. H5 subtype HPAIV-positive chicken serum was used as the primary antibody (1:5000) and HRP-labeled anti-chicken IgY was used as the secondary antibody (1:10000).
[0073] (2) Indirect ELISA verification of HA antigen epitope function Coating: Dilute H5 protein to 4 μg / mL with coating buffer, 100 μL / well, 3 replicates, incubate overnight at 4°C. Blank control: Coating buffer only.
[0074] Washing: Discard the coating solution, wash 3 times with PBST, soaking for 2 minutes each time, and pat dry.
[0075] Blocking: Block each well with 300 μL of 5% skim milk (prepared with PBST) and incubate at 37°C for 2 h.
[0076] Washing: Discard the blocking solution, wash 3 times with PBST, soaking for 2 minutes each time, and pat dry.
[0077] Primary antibody incubation: H5 subtype HPAIV positive chicken serum (PBST diluted 1:5000), 100 μL / well, incubated at 37℃ for 2 h. SPF negative chicken serum was set up as a negative control, and PBS was set up as a blank control.
[0078] Washing: Discard the primary antibody, wash 4 times with PBST, soaking for 2 minutes each time, and pat dry.
[0079] Secondary antibody incubation: HRP-labeled anti-chicken IgY antibody (PBST diluted, 1:10000), 100 μL / well, incubated at 37℃ for 1 h.
[0080] Washing: Discard the secondary antibody, wash 5 times with PBST, soaking for 2 minutes each time, and pat dry.
[0081] Color development: Add 100 μL of TMB substrate to each well and react at 37°C in the dark for 5-10 min (blue color develops).
[0082] Termination: Add 50 μL of 2 M H2SO4 to each well to stop the reaction (turns yellow).
[0083] Reading and Analysis: The microplate reader reads the absorbance at 450 nm (OD). 450 ).
[0084] Positive criterion: Signal-to-noise ratio (S / N): OD positive / OD negative ≥ 3.
[0085] Results: To verify the immunoreactivity and epitope function of recombinant H5 protein, confirmed H5 subtype HPAIV-positive chicken serum was used for Western blot and indirect ELISA detection.
[0086] Western blot results showed that ( Figure 6 A) Positive chicken serum can be identified as a specific band of approximately 65 kDa in the purified H5 protein sample, while no corresponding reaction band appears in the empty vector expression product.
[0087] The indirect ELISA results also showed ( Figure 6 (B) The recombinant H5 protein coated wells showed a significant binding reaction to positive chicken serum, but no reaction to negative serum. This indicates that the purified recombinant H5 protein retains the antigenic epitopes that can be recognized by specific antibodies, meeting the requirements for subsequent immunological and antibody evaluation experiments.
[0088] Example 4. Preparation and quality testing of immunogens (1) Vaccine emulsification: Take the purified and concentrated recombinant H5 protein (0.5 mg / mL), mix it with an equal volume of Freund's incomplete adjuvant, and emulsify it with a double-barreled syringe until it reaches the water-in-oil (W / O) state. It is qualified if it does not spread when dropped into water.
[0089] (2) Sterility test: Take 100 μL of emulsified vaccine and inoculate with LB medium, incubate at 37℃ for 72 h, and determine sterility if there is no turbidity.
[0090] (3) Storage: After repackaging, store at 4℃ (≤1 month) or at -80℃ for long-term storage, and avoid repeated freeze-thaw cycles.
[0091] Results: After thorough emulsification with Freund's incomplete adjuvant (IFA) using a double-barrel syringe, a stable water-in-oil emulsion was formed. This emulsion did not diffuse when dropped into water, meeting the requirements for immunization. No bacterial growth was observed after 72 hours of incubation on LB medium, indicating that the preparation process was aseptic and suitable for subsequent booster immunization of alpacas.
[0092] 1. Alpaca Immunity A healthy 2-year-old male alpaca was selected from an alpaca farm in Hulan District, Harbin City, Heilongjiang Province as the immunization animal. Peripheral blood was collected before immunization, and the hemagglutination inhibition (HI) test was used to detect the presence of specific antibodies against H5 subtype HA in the serum to confirm the baseline antibody level.
[0093] Immunization was performed via subcutaneous injection at multiple sites in the neck. The immunogens were inactivated HPAIV antigens of wild bird H5 subtype 2, 3, 4, and 4b branches, along with recombinant H5 protein antigens. The immunization schedule was one dose every four weeks, for a total of four immunizations.
[0094] 2. Alpaca serum antibody titer detection Alpaca serum was collected at specified time points after each immunization, and the changes in antibody titers against the H5 antigen in the serum were detected by HI test and indirect ELISA (HI ≥ 2). 5 The result was positive.
[0095] The purified recombinant H5 protein (0.5 μg / well) was coated onto an ELISA plate, and the binding capacity of the last alpaca serum to the H5 antigen was detected by indirect ELISA. Serum was serially diluted, with three replicates. Results are expressed as OD. 450 The secondary antibody used was an HRP-labeled goat anti-alpaca IgG heavy chain specific antibody (1:10000) to detect the level of binding antibodies against the H5 antigen in the serum after immunization.
[0096] Results: Alpacas were immunized four times according to the established immunization program. Serum samples were collected before each immunization to assess the humoral immune response level of the previous round of immunization (Table 9).
[0097] Table 9. Alpaca Immunization and Blood Collection Procedures
[0098] Pre-immunization (week 0) serum serum showed no specific antibodies against H5 subtype HA as detected by the HI test. With increasing immunization frequency, antibody levels against W41 and BQ6 antigens in alpaca serum gradually increased. The HI test results showed that specific antibodies were detectable after the initial immunization, and subsequent booster immunizations increased the hemagglutination inhibition titers of W41 and BQ6 to log210 and log27, respectively. Figure 7 A).
[0099] Indirect ELISA results showed that the binding response of alpaca serum to recombinant H5 protein gradually increased with the number of immunizations: week 0 was at background levels, week 4 showed a significant increase, week 8 further enhanced the response, and week 12 then plateaued. Figure 7 B).
[0100] To further assess the level of H5 protein-binding antibodies in serum after the last immunization (week 13), indirect ELISA was used to detect the last serum serum through two-fold serial dilutions. The results showed that the anti-H5 antibody titer in alpaca serum was 1:2048000 (…). Figure 7 C), can be used for the construction of nanobody libraries.
[0101] The above results indicate that the combined immunization strategy of inactivated virus and recombinant protein can effectively induce a stable humoral immune response in alpacas against the H5 subtype HPAIV.
[0102] 3. Total RNA was extracted from alpaca peripheral blood lymphocytes, and cDNA was obtained by reverse transcription. The VHH gene was then amplified by nested PCR. (1) The VH and VHH genes were amplified by PCR in one round. The primer sequences and amplification system (50 μL) are shown in Tables 10 and 11.
[0103] Table 10 Primer sequences for the first round of PCR
[0104] Table 11 First-round PCR amplification system
[0105] Reaction conditions: 94°C for 5 min; 94°C for 30 s, 56°C for 30 s, 72°C for 2 min, 20 cycles; 72°C for 10 min; 4°C infinity.
[0106] (2) The PCR products were subjected to agarose gel electrophoresis, and the gene with a band size of 700 bp was recovered from the gel.
[0107] (3) The gel recovery product was used as a template for the second round of PCR amplification. The primer sequences and amplification system (50 μL) are shown in Tables 12 and 13.
[0108] Table 12 Primer sequences for the second round of PCR
[0109] Table 13 Second-round PCR amplification system
[0110] Reaction conditions: 94°C for 5 min; 94°C for 30 s, 58°C for 30 s, 72°C for 2 min, 20 cycles; 72°C for 10 min; 4°C infinity.
[0111] (4) Use a PCR recovery kit to recover the PCR products and measure the DNA concentration.
[0112] result: On week 13 (7 days after the last immunization), 50 mL of anticoagulated peripheral blood was collected from alpacas. Peripheral blood mononuclear cells (PBMCs) were obtained by centrifugation using lymphocyte separation medium; the separation interface was clear. Figure 8 A total of approximately 1.2 × 10⁻⁶ was obtained. 8 One lymphocyte.
[0113] Total RNA was extracted from PBMCs and reverse transcribed to obtain cDNA, which was then used as a template for nested PCR amplification. The first round of PCR amplification yielded approximately 950 bp of a conventional antibody-encoded fragment and approximately 700 bp of a heavy chain antibody-encoded fragment. Figure 9 A). The 700 bp target band was purified by gel extraction and used as a template for a second round of PCR amplification, yielding a VHH target band of approximately 450 bp. Figure 9 B).
[0114] Example 5. Construction of VHH phage display library 1. The VHH product recovered from the second round of PCR 2th The pComb3× vector was subjected to Sfi-I double digestion, and the ligation system of the digestion product (100 μL) is shown in Table 14.
[0115] Table 14 Connection System
[0116] 20℃ 24 h; 70℃ 15 min; 4℃ ∞.
[0117] 300 ng of the ligation product was transferred into 250 μL of TG1 competent cells. The supernatant containing the phage was transferred to a centrifuge tube, and the bacterial pellet was frozen at -20°C for later use.
[0118] Add 12 g PEG8000 (4% w / v) and 9 g NaCl (3% w / v) to the supernatant, mix well, and incubate on ice for 30 min. Centrifuge at 15,000×g for 30 min at 4°C, discard the supernatant, and aspirate as much residual liquid as possible. Resuspend the phage pellet in 1.5 mL PBS buffer, transfer to a 1.5 mL EP tube, and centrifuge at 15,000×g for 5 min at 4°C to remove residual bacteria. Transfer the supernatant (phage library) to a new EP tube and store at 4°C. Phage titer determination. 10x serial dilution (10) -7 10 -8 10 -9 10 -10 Phage libraries were evenly spread on 2×YT plates (Amp+) and incubated overnight at 37°C. The colonies were counted the next day to calculate the phage library volume.
[0119] Forty-eight single clones were randomly selected and cultured at 37℃ and 220 rpm for 8 h. The cultured single clones were identified by culture PCR, and the positive rate of the recombinant phage library was calculated. The phage clones were identified by PCR using primers pComb3X-F and VHH-REV, and the system is shown in Table 15.
[0120] Table 15 PCR Identification System
[0121] Reaction conditions: 95°C for 5 min; 92°C for 1 min, 58°C for 30 s, 72°C for 1 min, 35 cycles; 72°C for 10 min; 4°C infinity.
[0122] The PCR products were subjected to agarose gel electrophoresis, and the target fragment was approximately 700-750 bp in size.
[0123] Results: The VHH gene and pComb3X vector purified by gel extraction were... Sfi- I undergo double enzyme digestion ( Figure 10 The purified gel product was ligated using T4 DNA ligase, electroporated into TG1 competent cells for amplification, and VHH was displayed on the surface of the phage with the help of helper phage M13KO7, thus constructing a VHH phage library.
[0124] The titer of the obtained phage library was determined to be 4.9 × 10⁻⁶. 13 The pfu / mL concentration indicates that a sufficient quantity of phage library was successfully obtained, meeting the library size requirements for subsequent phage panning experiments. Forty-eight single clones were randomly selected for colony PCR identification, and the results showed (…). Figure 11 The target fragment is approximately 700–750 bp, with an insertion positivity rate of 95.8%.
[0125] 2. Construction and identification of pLVSIN-H5 recombinant plasmid Based on the obtained full-length common sequence of the H5 gene (1704 bp), pLVSIN vector homologous arms were added to both ends of the sequence, and the whole gene was synthesized by Jilin Kumei Biotechnology Co., Ltd. The synthesized H5 gene with homologous arms was then homologously ligated into the linearized pLVSIN vector in a 10 μL volume (see Table 16).
[0126] Table 16 Homologous recombination linkage system
[0127] Connect at 37°C for 30 minutes.
[0128] The recombinant plasmid pLvsin-H5 was transformed into DH5α competent cells, and the plasmid was extracted. The recombinant plasmid pLvsin-H5 was identified by PCR using H5 full-length gene-specific primers. The specific primer sequences are shown in Table 17.
[0129] Table 17 H5 full-length gene-specific primer sequences
[0130] The PCR products were subjected to agarose gel electrophoresis, and the products with the correct band size were sent to Jilin Kumei Biotechnology Co., Ltd. for sequencing.
[0131] Results: Construction and identification of pLVSIN-H5 recombinant plasmid The sequence of the A / greylag goose / Netherlands / 20016414-001 / 2020(H5N8) strain (full-length common sequence of the H5 gene) obtained through screening was cloned into the pLVSIN vector via homologous recombination. PCR identification of the recombinant plasmid showed that a specific band of approximately 1700 bp was amplified. Figure 12 The sequencing results of the positive recombinant plasmid were consistent with the target sequence, indicating that the pLVSIN-H5 recombinant plasmid was successfully constructed.
[0132] Example 6. Construction of a lentivirus-mediated stable 293T-H5 expression cell line 24 hours before transfection, at 5×10 6 293T cells were seeded at a density of 10 cm cells / cells to achieve 70–80% cell confluency at transfection. Virus was prepared using a three-plasmid lentivirus packaging system, with a total plasmid amount of 20 μg, including 10 μg pLVSIN-H5, 8 μg packaging plasmid gag-pol, and 2 μg envelope plasmid VSV-G. The plasmid-liposome complex was prepared according to the Lipofectamine 3000 manufacturer's instructions and added to the cells for transfection. After 6–8 h of transfection, the medium was replaced with fresh complete medium for further culture.
[0133] Viral packaging efficiency was indirectly assessed by the fluorescence signal of cells after transfection. Cell culture supernatant was collected at 48 h and 72 h post-transfection, and stable expression cell populations were obtained by selection with puromycin. The supernatant was filtered through a 0.22 μm filter and then combined. The viral supernatant was concentrated using the PEG 8000 precipitation method, incubated overnight at 4°C, centrifuged at 4000×g for 30 min to collect the viral pellet, resuspended in PBS, aliquoted, and stored at -80°C for later use.
[0134] 24 h before infection, 293T cells were seeded in 6 cm culture dishes to achieve 50–60% cell confluence at infection. A suitable amount of concentrated virus solution was added, supplemented with polybrene (final concentration 8 μg / mL) to promote infection. After 12–16 h of virus incubation, the medium was replaced with fresh complete medium. 48 h post-infection, puromycin (final concentration 10 ng / mL) was added for selection. Cells were continuously passaged and the selection pressure was maintained. After 2–3 passages of selection, the cells showed stable growth and no significant cell death, indicating a cell line with stable H5 gene expression.
[0135] Results: Based on the successfully constructed pLVSIN-H5 recombinant plasmid, virus was packaged in 293T cells using a three-plasmid lentiviral packaging system. Cells were in good condition after transfection. Figure 13E–H), no significant cytotoxicity was observed. Fluorescent signals were observed in packaging cells 24 h post-transfection. Figure 13 B), the fluorescence signal was significantly enhanced after 48 h ( Figure 13 C), the fluorescence signal remained stable for 72 h. Figure 13 D); while untransfected cells showed no fluorescent signal, indicating successful lentivirus packaging ( Figure 13 A). Viral supernatant was collected at 48 h and 72 h post-transfection and concentrated by PEG precipitation to obtain lentivirus preparation solution.
[0136] The concentrated lentivirus was used to infect target 293T cells, which were then continuously cultured under puromycin selection pressure. Infected cells survived and proliferated normally under selection conditions. Figure 14 After 2–3 generations of selection, the cells showed good growth and stably expressed fluorescent markers (F–H). Figure 14 C, D). Uninfected control cells gradually died within 24–72 h, and no fluorescent signal was observed. Figure 14 (A, E). The above results indicate that the 293T-H5 cell line with stable H5 gene expression was successfully obtained.
[0137] Western blot results showed that ( Figure 15 A specific band (approximately 72 kDa) consistent with the theoretical molecular weight of the H5 protein was detected in cell membrane protein samples from the 293T-H5 stable cell line, while no corresponding signal was detected in uninfected 293T cells.
[0138] Indirect immunofluorescence results further confirmed ( Figure 16 A distinct specific fluorescent signal was observed on the surface of the 293T-H5 cell membrane, while no fluorescent signal was observed in uninfected 293T cells, indicating that the H5 protein was successfully anchored to the cell membrane. These results consistently validate the stable membrane expression of the H5 protein in the stable 293T-H5 cell line, providing a reliable cell model basis for subsequent phage library selection.
[0139] Example 7. Cell-panning and enrichment of phage libraries 1. Negative screening (1) Preparation of negative cells Digestion 3.5 × 10 8 Centrifuge 293T cells at 4°C and 750×g for 3 min, and discard the supernatant.
[0140] Resuspend and wash cells twice with 50 mL PBS, centrifuge at 750×g for 3 min at 4°C, and discard the supernatant.
[0141] Transfer the cells to a new centrifuge tube, resuspend in 2 mL of PBS, centrifuge at 750×g for 3 min, and discard the supernatant.
[0142] (2) Phage pre-adsorption Pre-adsorption of the phage library was performed using a cell:phage ratio of 1:500.
[0143] The phages were pre-incubated with 5% skim milk powder for 15 min to block them.
[0144] Add the phage mixture to the 293T cell pellet, gently invert and resuspend, and let stand at room temperature for 30 min to pre-clear nonspecific binding.
[0145] Centrifuge at 4°C, 10,000×g for 2 min, and collect the supernatant containing phages for positive selection.
[0146] 2. Positive selection (1) Preparation of positive cells Digestion 3.5 × 10 8 Centrifuge 293T-H5 cells at 4°C and 750×g for 3 min, and discard the supernatant.
[0147] Transfer the cells to a new centrifuge tube, resuspend and wash twice with 2 mL PBS, centrifuge at 750×g for 3 min, and discard the supernatant.
[0148] (2) Phage binding Add the phage supernatant, which has been pre-adsorbed with negative ions, to 293T-H5 cells, gently invert and resuspend, and incubate at room temperature for 30 min. Wash three times with PBS, centrifuge at 750×g for 3 min at room temperature, and discard the supernatant.
[0149] (4) Acid elution and neutralization Resuspend the phage in 0.1 M glycine solution (pH 2.2), mix well, and incubate at room temperature for 10 min. Then neutralize with 2 M Tris solution (pH 8.0) (approximately 1 / 10 of the volume), mix well, and centrifuge at 10,000 × g for 2 min at 4°C. Collect the supernatant containing the phage (Output).
[0150] (5) Infection with TG1 Add the Output supernatant to TG1 cells in logarithmic growth phase (OD600≈0.6–0.8), incubate at 37°C for 15 min, add preheated SB medium, and continue culturing for 30–60 min to restore growth.
[0151] (6) Output titer determination The infected bacterial culture was serially diluted 10-fold, and 100 μL of each dilution was evenly spread on 2×YT solid plates containing Amp and incubated overnight at 37°C. The output was calculated.
[0152] (7) Phage amplification and preparation of the next round of input After incubation, the infected TG1 bacterial culture was expanded to the logarithmic growth phase, and then helper phages were added for infection. The culture was then carried out under standard conditions to induce phage production. After incubation, the supernatant was collected by centrifugation, and the phages were enriched using the PEG8000 / NaCl precipitation method. The amplified phages were resuspended in PBS to obtain amplified phages. The amplified phages were serially diluted and plated for counting as described above to obtain the input required for the next round of panning. The amplified phages were then stored at 4°C for later use.
[0153] (8) Continuous panning and enrichment evaluation The above process is followed for three consecutive rounds of screening. Input and Output titers are recorded in each round, and the Output / Input ratio is calculated as an enrichment metric to evaluate screening efficiency and specific enrichment trends.
[0154] Results: The phage nanobody library was screened using the stable 293T-H5 cell line, with 293T blank cells used as a negative control. Three rounds of screening were performed consecutively. An equal amount of phage was used as input in each round (Inputphage: 5.0 × 10⁻⁶). 10 (pfu / well), "P output" is the amount of phage eluted from the 293T-H5 stable cell line in each round of screening, "N output" is the amount of phage harvested from 293T blank cells, and the recovery rate is expressed as "P output / Input". The specific enrichment of the library is assessed by comparing the titer change (P / N) of phage eluted from positive and negative cells.
[0155] The results are shown in Table 18. With the increase of the number of panning rounds, the number of phages recovered from 293T-H5 cells increased in each round, from 8.0 × 10⁻⁶ in the first round. 6 The pfu / well ratio increased to 5.3 × 10⁻⁶ in the third round. 8 pfu / well; meanwhile, the number of phages recovered from 293T blank cells gradually decreased. Correspondingly, the P / N value decreased from 1.6 × 10⁻⁶ in the first round. 1 Upgraded to 4.0×10 in the second round. 2 And in the third round, it was further increased to 6.6×10 3 This indicates that continuous panning based on the 293T-H5 stable cell line can effectively enrich phages that specifically bind to the H5 protein.
[0156] Table 18 Enrichment of H5-specific bacteriophages
[0157] 3. Phage ELISA identification of positive clones (1) Add 1 mL of 2×YT culture medium (Amp) to each well of a 96-well deep-well plate. + After three rounds of selection, single colonies from 2×YT plates were randomly selected and inoculated into 96-well culture plates, and incubated overnight at 37°C.
[0158] (2) Transfer 10 μL of the overnight culture to a new 9-well deep-well plate and incubate at 37°C and 220 rpm for 3-4 h (OD). 600 = 0.6–0.8), add 0.2 mM IPTG to each well, and induce expression at 37°C for 6 h.
[0159] (3) The next day, centrifuge at 4000 rpm for 10 min and discard the supernatant.
[0160] (4) Place at -80°C for 30 min and at 37°C for 10 min to lyse the bacteria.
[0161] (5) Resuspend the bacterial sediment in 100 μL PBS in each well, shake at high speed for 30 min, centrifuge at 4000 rpm for 10 min, and 100 μL of supernatant is the crude extract of nanoantibody, which is used as the primary antibody for phage ELISA.
[0162] (6) Dilute the recombinant H5 protein with coating buffer to 4 μg / mL, 100 uL / well, 3 replicates, and incubate overnight at 4°C.
[0163] (7) ELISA reaction, the secondary antibody is HRP anti HA-Tag Antibody (1:10000).
[0164] (8) Expand the culture of positive clones of bacteria that only have recombinant H5 protein, send part of them to Jilin Kumei Biotechnology Co., Ltd. for sequencing, and freeze part of them at -80°C.
[0165] Results: Ninety-six monoclonal antibodies were randomly selected from the plates obtained in the third round of cell line panning. These antibodies were induced to express a crude extract of soluble nanobodies, and their reactivity with recombinant H5 protein was detected by indirect ELISA. OD values of each clone were measured using PBS as a negative control. 450 The absorbance value is nm. Clones with an absorbance value of ≥3 / PBS absorbance value are considered positive clones.
[0166] The results are as follows Figure 17As shown, among the 96 monoclonal antibodies tested, 94 clones were identified as positive, with a positive rate of 97.9%, indicating that the nanobody library obtained after three rounds of screening has a good enrichment effect and binding activity for recombinant H5 protein.
[0167] Amino acid sequence alignment revealed that some clones possessed completely identical CDR3 sequences, indicating the presence of dominant clonal amplification. The largest clonal family accounted for 37 / 94 (39.4%). To avoid interference from duplicate clones in subsequent functional screening, redundancy was removed based on the principle of completely different CDR3 amino acid sequences, ultimately resulting in 30 representative VHH strains with unique CDR3 sequences. Figure 18 Apart from the dominant clone, the remaining clones still showed significant differences in CDR3 length and sequence, indicating that the library maintained good structural diversity while achieving specific enrichment.
[0168] Example 8. Prokaryotic expression, purification, and identification of candidate nanobodies (VHH-His) 1. Construction and identification of VHH-His prokaryotic expression vector Based on the obtained VHH gene, prokaryotic expression vector pET-22b(+) homologous arms were added to both ends of the sequence, and the whole gene was synthesized by Jilin Kumei Biotechnology Co., Ltd.
[0169] The synthesized VHH gene with a homologous arm was homologously ligated into the linearized vector pET-22b(+). The recombinant plasmid pET-22b-VHH was transformed into DH5α competent cells, and plasmid extraction was performed.
[0170] The recombinant plasmid pET-22b-VHH was identified by PCR using specific primers. The primer sequences are shown in Table 19.
[0171] Table 19 VHH gene-specific primer sequences
[0172] The PCR products were subjected to agarose gel electrophoresis, and the products with the correct band size were sent to Jilin Kumei Biotechnology Co., Ltd. for sequencing.
[0173] Results: Based on the VHH gene sequences obtained through screening, the sequences were cloned into the prokaryotic expression vector pET-22b(+) via homologous recombination. PCR identification of the recombinant plasmids showed that each plasmid amplified a specific band of approximately 400 bp. Figure 19 The sequencing results of the PCR-positive recombinant plasmids were consistent with the target sequence, indicating that the nine pET-22b-VHH-His recombinant plasmids were successfully constructed and can be used for subsequent protein expression and functional evaluation experiments.
[0174] 2. Prokaryotic expression, purification, and concentration of VHH-His The correctly sequenced recombinant plasmid pET-22b-VHH was transformed into BL21(DE3) competent cells. Results: Nine successfully constructed pET-22b-VHH-His recombinant plasmids were transformed into BL21(DE3) cells for induced expression. The soluble supernatant was purified by Ni-NTA affinity, dialyzed, and concentrated by ultrafiltration. Western blot analysis of the concentrated supernatant showed... Figure 20 A specific band appeared at approximately 17 kDa, consistent with the theoretical molecular weight of VHH, indicating that the expression product was a target His tag fused with VHH protein. SDS-PAGE analysis after concentration showed (…). Figure 20 (B) All samples showed a single, clear band with no obvious impurities, and the purity was above 95%, meeting the requirements for subsequent functional experiments.
[0175] 3. Results of in vitro binding and preliminary functional screening of candidate nanobodies (VHH-His) Indirect ELISA determination of VHH-His binding capacity (EC) 50 ) The recombinant H5 protein was diluted to 4 μg / mL with coating buffer, 100 μL / well, 3 replicates, and incubated overnight at 4°C. The next day, after washing with PBST, 300 μL of 5% skim milk (prepared with PBST) was added to each well for blocking, and the plates were incubated at 37°C for 2 h. After washing, the purified nanobody VHH-His was serially diluted with PBST as primary antibody, 100 μL / well, and incubated at 37°C for 1 h. After washing, HRP-labeled anti-His-Tag antibody (PBST dilution, 1:10000) was added as secondary antibody, 100 μL / well, and incubated at 37°C for 1 h. 100 μL of TMB substrate was added to each well, and the reaction was carried out at 37°C in the dark for 5–10 min. The reaction was terminated by adding 50 μL of 2 M H2SO4 to each well. OD was measured using a microplate reader. 450 absorbance value in nm.
[0176] Using PBS as a negative control, antibody concentration-OD plots were generated. 450 The curves were fitted using a nonlinear regression model (four-parameter logistic model) with GraphPad Prism software to calculate the half-maximum binding concentration (EC50). 50 ).
[0177] Results: Nine prokaryotically expressed and purified nanobodies, VHH-His, were detected by indirect ELISA, and antibody concentration – OD was analyzed. 450 Data fitting ( Figure 21The results showed differences in binding affinity between different antibodies. VHH36-His (EC) 50 = 0.1555 μg / mL) and VHH45-His (EC 50 = 0.1594 μg / mL) showed the lowest EC50. 50 The value is followed by VHH26-His (EC). 50 = 0.2021 μg / mL), VHH8-His (EC 50 = 0.2373 μg / mL) and VHH70-His (EC 50 = 0.2497 μg / mL Figure 21 A). VHH83-His (EC) 50 = 0.3758 μg / mL) and VHH46-His (EC 50 = 0.4181 μg / mL) has relatively weak binding ability, while VHH6-His (EC) has relatively weak binding ability. 50 = 0.5858 μg / mL) and VHH80-His (EC 50 = 0.7316 μg / mL) with the highest EC50 value ( Figure 21 B) indicates that its ability to bind to antigens is relatively low.
[0178] (2) Evaluation of the specificity and cross-reactivity of VHH-His The binding of nanobodies to different prevalent branches of H5 subtype HPAIV, H5 subtype LPAIV, and other subtype strains was detected using an indirect ELISA method. Representative strains were purified by ultracentrifugation and coated at appropriate concentrations onto 96-well plates, incubated overnight at 4°C. OD0.05 was used as the metric. 450 The criterion for a positive result is nm ≥ 3 × 10⁻⁶ for the negative control. Results are expressed as average OD₂O₃. 450 The values were plotted as a heatmap. Nanobodies that bind only to strains of branch 2.3.4.4b were selected for subsequent functional evaluation.
[0179] Results: The binding ability of nine prokaryotically expressed and purified VHH-His strains to different H5 subtype HPAIV epidemic branches, H5 subtype LPAIV, and other HA subtype strains was detected by indirect ELISA. The strain information is shown in Table 20.
[0180] Table 20 Information on specificity and cross-reactivity experimental strains
[0181] Table 21 Information on specificity and cross-reactivity experimental strains
[0182] The results are shown in the figure. Figure 22 All nine VHH-His strains showed significant binding signals on strain 2.3.4.4b (FZQ1-2). For other H5 subtype HPAIV strains (2.3.4.4e, 2.3.4.4g, 2.3.4.4h, 2.3.2.1c), H5 subtype LPAIV strains, and other subtypes (H1N1, H3N8, H7N4, H9N2), no significant binding signals were detected in any of the VHH-His strains. 450 The values were close to the background level. The results showed that all nine VHH-His strains exhibited specific binding ability to strains from branch 2.3.4.4b, while no obvious cross-reactivity was observed with other H5 branches and common LPAIVs, suggesting that their recognition epitopes are relatively conserved and branch-specific within branch 2.3.4.4b.
[0183] Table 22
[0184] VHH46 nucleotide sequence: (SEQ ID NO.19) CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGCCTGGGGGGTCTCTAAAACTCTCCTGTACACCCTCTATTAGCATCTTCAGTATCTATGTTAAAGAATGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGTCGCAACCCTTATTACTAGTGGTAGCCTTATCAGGGA GGACTATGCAGACTTCGTGAAGGGCCGATTCACCATCTCCGAAGACAACACCAAGAACACGGTCTATTTGCAAATGAACAGCCTGACACCTGAGGACACGGCCGTCTATTACTGTAAGATGGACTCCTACTGGGGCCAGGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGCCACTAGT; VHH46 amino acid sequence: (SEQ ID NO.20) QVQLQESGGGSVQPGGSLKLSCTPSISIFSIYVKEWYRQAPGKQRELVATLITSGSLIREDYADFVKGRFTISEDNTKNTVYLQMNSLTPEDTAVYYCKMDSYWGQGTQVTVSSAAATS.
Claims
1. A nanobody VHH46 targeting highly pathogenic avian influenza virus of subtype H5, branches 2, 3, 4, and 4b, characterized in that, The amino acid sequence of CDR-1 of the nanobody is shown in SEQ ID NO.13, the amino acid sequence of CDR-2 of the nanobody is shown in SEQ ID NO.15, and the amino acid sequence of CDR-3 of the nanobody is shown in SEQ ID NO.
17.
2. The nanobody VHH46 according to claim 1, characterized in that, The amino acid sequence of FR1 of the nanobody is shown in SEQ ID NO.12, the amino acid sequence of FR2 of the nanobody is shown in SEQ ID NO.14, the amino acid sequence of FR3 of the nanobody is shown in SEQ ID NO.16, and the amino acid sequence of FR4 of the nanobody is shown in SEQ ID NO.
18.
3. A nanobody VHH46 targeting highly pathogenic avian influenza virus of subtype H5, 2, 3, 4, and 4b, characterized in that, The full length of the variable region of the nanobody VHH26 is shown in SEQ ID NO.
20.
4. The gene encoding the nanobody of claim 1.
5. A kit for detecting highly pathogenic avian influenza virus of subtype H5, branch 2, 3, 4, and 4b, characterized in that, The kit includes the nanobody VHH46 as described in any one of claims 1-3.
6. A recombinant vector, characterized in that, The recombinant vector contains the gene described in claim 4.
7. A recombinant microbial cell, characterized in that, The recombinant microbial cell contains the gene described in claim 4.
8. The use of the nanobody VHH46 against highly pathogenic avian influenza virus of subtype H5 2.3.4.4b as described in any one of claims 1-3, the gene as described in claim 4, the recombinant vector as described in claim 6, or the recombinant microbial cell as described in claim 7 in the preparation of a kit for detecting highly pathogenic avian influenza virus of subtype H5 2.3.4.4b.
9. The application according to claim 8, characterized in that, The nanobody VHH46 described in claim 1 in the kit is a detection antibody, and the HRP-labeled anti-His-Tag antibody is a capture antibody.
10. The application according to claim 8, characterized in that, The kit is an indirect ELISA kit.
